Information Hub

Clinical News

2019-10-24

Olaparib showed clinical benefits in heavily pretreated mCRPC with homologous recombination repair (HRR) gene mutations

A phase III study (PROfound) showed that homologous recombination repair (HRR) gene mutations were associated with greater clinical benefits compared with physician’s choice of enzalutamide or abiraterone plus prednisone in heavily pretreated mCRPC patien

Source:

ESMO Congress 2019

2019-10-24

Veliparib demonstrated clinical benefits in patients with ovarian cancer

In the phase 3 VELIA trial, veliparib showed a good therapeutic effect when added to standard first-line chemotherapy and continued as maintenance therapy in ovarian cancer.

Source:

N Engl J Med. 2019

2019-10-24

Pemigatinib demonstrates clinical activity in second-line FGFR2 fusion cholangiocarcinoma

According to findings from the phase 2 FIGHT-202 clinical trial presented at ESMO 2019, pemigatinib, a selective inhibitor of FGFR1, 2, and 3, showed clinical benefits in previously treated advanced or metastatic cholangiocarcinoma (CCA) patients with an

Source:

2019 ESMO Congress

2019-09-23

Genetic alterations associated with immunotherapy response in advanced NSCLC

The results of a phase III study (MYSTIC) showed that ARID1A mutation were associated with clinical benefits in patients received durvalumab plus tremelimumab combination therapy

Source:

WCLC 2019

2019-09-23

Dabrafenib and trametinib shows promising activity in pre-treated BRAF V600E/K mutated tumors

In NCI-MATCH trial (Arm H), dabrafenib plus trametinib showed antitumor activity in patients with pre-treated tumors harboring BRAF V600E/K mutations (except melanoma, thyroid cancer, and colorectal cancer).

Source:

J Clin Oncol

2019-09-23

Molecular-matched therapy improves overall survival in pancreatic cancer

The results from the Know Your Tumor (KYT) presented at 2019 ASCO demonstrated a significant improvement in overall survival in pancreatic cancer patients with highly actionable alterations that received matched targeted therapy versus those only received

Source:

J Clin Oncol 37, 2019

2019-08-23

BLU-667 demonstrates the antitumor activity in RET fusion-positive NSCLC and other cancers

RET rearrangements have been found to promote cell proliferation in cancer, and a phase I study showed BLU-667 has antitumor activity in patients with RET fusion-positive tumor.

Source:

ASCO annual meeting 2019

2019-08-23

TAK-788 Shows Clinical Benefit in NSCLC Patients with EGFR Exon 20 Insertions

No currently approved drug can target the EGFR exon 20 insertions in NSCLC, and TAK-788 is a potential treatment for these type of patients.

Source:

J Clin Oncol 37, 2019

2019-08-23

Olaparib shows efficacy in castration-resistant prostate cancer with defects in DNA-repair genes.

The PARP inhibitor olaparib demonstrates antitumor activity in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene defects.

Source:

J Clin Oncol 37, 2019

2019-08-05

Combination Immunotherapy Prolongs Overall Survival of mCRC

The results of a phase II study showed that the clinical efficacy of the combination of durvalumab and tremelimumab in patients with mCRC. Furthermore, the results indicated that bTMB can be used to select patients who benefit from immunotherapy treatment

Source:

ASCO annual meeting 2019